dpp4 vs glp 1 DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits Dipeptidyl Peptidase 4: DPP4 -

The FDA has issued guidance about the risks of compounded semaglutide, including concerns about sterility, potency consistency, and salt form differences

Tirzepatide: Nausea 12-33%, diarrhea 12-21%, vomiting 5-13%

Additionally, GLP-1 medications can affect the absorption of some oral medicines by slowing gastric emptying

Nwafor IC, Manduna IT

BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma

Relevant English-language studies were identified through PubMed, Scopus, Web of Science, Embase, and Google Scholar up to May 2025 using combinations of the terms GLP-1 receptor agonist, SGLT2 inhibitor, gut microbiota, type 2 diabetes, renal, and cardiovascular. Both preclinical and clinical investigations were considered, with an emphasis on peer-reviewed studies addressing microbiota composition, metabolite shifts, and systemic effects